President Trump has launched TrumpRx.gov, a site designed to take advantage of pricing agreements with leading pharmaceutical manufacturers to offer lower prices on prescriptions, including popular GLP-1 medications.
The site allows consumers to directly buy 40 popular — and expensive — medications and pay prices in line with the lowest paid by other developed nations, known as most-favored-nation or MFN prices. According to a White House fact sheet, monthly costs for Ozempic and injectable Wegovy drop from $1,028 and $1,349, respectively, to an average of $350 and as low as $199, depending on the dosage.
The launch features drugs made by five leading pharmaceutical companies that have reached MFN agreements with TrumpRx.gov: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer. Additional drugs from other companies that have signed MFN agreements will be made available in coming months. The new site also offers discounts on commonly used fertility medications and other high-cost drugs used to treat COPD, asthma, osteoporosis and diabetes.
GoodRx is a core integration partner for TrumpRx.gov and, at launch, is the integrated pricing source for Pfizer, including more than 30 Pfizer medications. Additional manufacturer integrations are expected to follow.
Advertisement
“Transparent direct-to-consumer prescription pricing helps to ensure millions of Americans have access to the healthcare they deserve,” said Wendy Barnes, President and CEO of GoodRx in a statement. “GoodRx gives manufacturers a proven way to launch discounted cash pricing at scale and extend it directly into TrumpRx.”
